AstraZeneca’s Farxiga Fails To Get FDA OK As Insulin Supplement In Type 1 Diabetes

 
• By Sten Stovall

The UK pharma said the FDA had issued a complete response letter, declining its application for using Farxiga in the new T1D indication. Analysts suspect worries over diabetic ketoacidosis risk lie behind the rejection.

Laptop
The FDA’s CRL will have said the Farxiga application cannot be approved in its present form • Source: Shutterstock

More from New Products

More from Scrip